Company Overview
About NewLimit
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
Business Model & Competitive Advantage
The T cell rejuvenation approach addresses a fundamental problem in aging immunity: CD8 T cells progressively lose their ability to kill cancer cells and clear infections as humans age, contributing to increased cancer risk and infectious disease vulnerability in older adults. NewLimit's transcription factor approach reprograms these aged cells back toward a youthful functional state without genetic modification, potentially enabling a therapeutic that restores immune function across multiple age-related conditions.
Competitive Landscape 2025–2026
Eli Lilly's direct investment is the most significant institutional signal: Lilly is one of the world's largest pharmaceutical companies with a deep oncology and immunology portfolio, and its $45 million strategic investment indicates active interest in licensing or collaborating on NewLimit's platform for specific disease indications. The $1.62 billion valuation reflects both the technical milestone and the commercial potential Lilly's diligence validated.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
NewLimit is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
NewLimit has achieved $130M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare NewLimit with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from NewLimit? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim NewLimit Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention NewLimit vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →